Bullish & Foolish
Full ACXP fundamentals All 466 on the Survival Watch

ACXPAcurx Pharmaceuticals, Inc.

Is Acurx Pharmaceuticals struggling financially?

Yes, by its own account. Acurx Pharmaceuticals told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

24/100

Fragile

Sector
Biotech/Pharma
Market cap
$7.7M
Source filing
10-Q 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 9months

    If the burn speeds up

    Empty by Mar 2027

  • 13months

    If it eases off

    Empty by Jul 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$10.7M

÷

Cash burned over the last 12 months

$11.3M

What Acurx Pharmaceuticals told the SEC

…equity financing and grant funding, but cannot assure that such financing and funding will be available at acceptable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that the…

Acurx Pharmaceuticals, Inc., Form 10-Q, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 218.5% share-count increase The company issued stock. Each share now owns 68.6% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 30% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt